IL-4 as therapy for non-Hodgkin's lymphoma: Possibilities but major challenges

Leukemia and Lymphoma

Volumn 48, Issue 7, 2007, Pages 1259-1260

  Martin, Peter ^a   Leonard, John P ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; INTERLEUKIN 4; PREDNISONE; PROTEIN BCL 6; RITUXIMAB; VINCRISTINE;

B CELL LYMPHOMA; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENTIATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; LARGE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; NOTE; PRIORITY JOURNAL; PROGNOSIS; SIGNAL TRANSDUCTION; TH2 CELL; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; INTERLEUKIN-4; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; LYMPHOMA, NON-HODGKIN;

EID: 34447572815     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701416481     Document Type: Note

References (6)

1. Kurtz, D. M., Tschetter, L. K., Allred, J. B., Geyer, S. M., Kurtin, P. J. and Putnam Jr, W. D. (2007) Subcutaneous interleukin-4 (IL-4) for relapsed and resistant non-Hodgkin lymphoma: A phase II trial in the North Central Cancer Treatment Group, NCCTG 91-78-51. Leukemia Lymphoma, 48, pp. 1290-1298.
2. Taylor, C. W., LeBlanc, M., Fisher, R. I., Moore, D FS, Roach, R. W. and Elias, L. (2000) Phase II evaluation of interleukin-4 in patients with non-Hodgkin's lymphoma: A Southwest Oncology Group Trial. Anticancer Drugs, 11, pp. 695-700.
3. Rosenwald, A., Wright, G., Chan, W. C., Connors, J. M., Campo, E. and Fisher, R. I. (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med, 346, pp. 1937-1947.
4. Nechushtan, H., Ding, F., Rosado, M. F., Singal, R. and Alizadeh, A. A. (2005) Distinct IL-4-induced gene expression, proliferation, and intracellular signaling in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas. Blood, 105, pp. 2924-2932.
5. Winter, J. N., Weller, E. A., Horning, S. J., Krajewska, M., Variakojis, D. and Habermann, T. M. (2006) Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: A prospective correlative study. Blood, 107, pp. 4207-4213.
6. Nechushtan, H., Rosenblatt, J. D. and Lossos, I. S. (2004) IL-4 affects proliferation, chemosensitivity and rituximab sensitivity of germinal center B-cell like (GCB) and activated B-cell like (ABC) diffuse large B-cell lymphoma differently. ASH Ann Meeting Abs, 104, p. 242.